MetaCap

Alcon (ALC) vs RxSight (RXST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alcon (ALC) has outperformed RxSight (RXST) over the past year, losing 3.0% versus a loss of 56.0%. Over five years, ALC leads with a -4.6% price change compared with -63.9% for RXST. Alcon is the larger company by market cap ($35.70 billion vs $187.4 million), about 190.5 times the size.

Alcon pays a dividend yielding 0.48%, while RxSight does not currently pay one. Alcon converts more of its revenue into profit, with a net margin of 9.4% versus -29.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALC-3.00%RXST-55.96%
+33%-13%-60%
Nov 21, 20251 yearNov 20, 2026
ALC-9.84%RXST-66.94%
+377%+145%-88%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALC versus RXST key metrics
MetricALCRXST
Share price$74.31$4.47
Market cap$35.70B$187.42M
1-day change-0.26%-3.04%
YTD return-5.71%-57.10%
1-year return-3.00%-55.96%
5-year return-4.62%-63.86%
P/E ratio (TTM)54.24—
Forward P/E19.05—
EPS (TTM)$1.37$-1.29
Dividend yield0.48%0.00%
Annual dividend$0.353$0.00
Revenue (latest FY)$10.40B$134.48M
Revenue growth (YoY)+4.94%-3.89%
Net income (latest FY)$980.00M$-38.94M
Gross margin55.24%76.60%
Operating margin13.08%-35.84%
Net margin9.42%-28.96%
52-week high$87.64$13.22
52-week low$61.84$4.11
Distance from 52-week high-15.21%-66.19%
Analyst consensusbuyhold
Avg. price target upside+9.37%+36.47%
Average volume2.01M826.96K
Shares outstanding480.40M41.93M
Employees25,000461
SectorHealth CareHealth Care
IndustryOphthalmic GoodsOphthalmic Goods

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alcon is about 190.5 times larger than RxSight by market value ($35.70B vs $187.42M).
  • ALC has outperformed RXST by 53.0 percentage points over the past year.
  • Alcon is more profitable, keeping 9.4 cents of every revenue dollar as net income versus -29.0 cents for RxSight.
  • Alcon grew revenue faster in its latest fiscal year (+4.94% vs -3.89%).

About Alcon

ALC stock →

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.

Health Care · Ophthalmic Goods · 25,000 employees

About RxSight

RXST stock →

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Health Care · Ophthalmic Goods · 461 employees

ALC vs RXST FAQ

Which is bigger, Alcon or RxSight?

Alcon (ALC) is larger, with a market capitalization of $35.70B compared with $187.42M for RxSight (RXST).

Which stock has performed better over the past year, ALC or RXST?

ALC returned -3.00% over the past 12 months, compared with -55.96% for RXST (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Alcon or RxSight?

Alcon pays a dividend yielding 0.48%, while RxSight does not currently pay a regular dividend.

Are Alcon and RxSight in the same industry?

Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.

More comparisons